Key Points
- EVP Paul Mahon sold 8,300 UTHR shares on Jan. 2 at an average price of $485.43 for a total of $4,029,069, reducing his stake by 18.41% to 36,781 shares (≈$17.85M).
- Company valuation and analyst sentiment: United Therapeutics trades around the mid-$400s with a $21.39B market cap, P/E of 18.82 and an average analyst price target of $505, with the consensus rating at "Moderate Buy" (8 Buys, 3 Holds).
- Recent quarter showed earnings beat but mixed revenue: UTHR reported $7.16 EPS (above the $6.89 estimate) and revenue of $799.5M (slightly below estimates) with a 40.65% net margin and 18.83% ROE, and revenue up 6.8% year‑over‑year.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the company's stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $485.43, for a total transaction of $4,029,069.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares in the company, valued at approximately $17,854,600.83. The trade was a 18.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
United Therapeutics Trading Up 1.9%
NASDAQ UTHR opened at $496.72 on Friday. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $519.99. The company has a 50 day moving average of $478.35 and a 200-day moving average of $394.39. The firm has a market cap of $21.39 billion, a price-to-earnings ratio of 18.82, a PEG ratio of 4.68 and a beta of 0.84.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts' consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same period in the prior year, the company earned $6.39 EPS. United Therapeutics's revenue for the quarter was up 6.8% on a year-over-year basis. On average, analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Clearstead Advisors LLC lifted its holdings in shares of United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company's stock worth $117,000 after acquiring an additional 23 shares during the last quarter. Bessemer Group Inc. increased its holdings in shares of United Therapeutics by 2.6% during the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company's stock worth $472,000 after buying an additional 28 shares in the last quarter. Archer Investment Corp increased its holdings in shares of United Therapeutics by 9.5% during the third quarter. Archer Investment Corp now owns 356 shares of the biotechnology company's stock worth $149,000 after buying an additional 31 shares in the last quarter. F m Investments LLC lifted its stake in shares of United Therapeutics by 1.3% in the 2nd quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company's stock valued at $741,000 after acquiring an additional 33 shares during the last quarter. Finally, HB Wealth Management LLC boosted its stake in shares of United Therapeutics by 2.9% during the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company's stock valued at $355,000 after purchasing an additional 35 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on UTHR shares. Jefferies Financial Group restated a "buy" rating and issued a $575.00 price objective on shares of United Therapeutics in a report on Wednesday, November 19th. Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a research note on Wednesday, October 29th. Royal Bank Of Canada boosted their target price on United Therapeutics from $569.00 to $587.00 and gave the stock an "outperform" rating in a report on Thursday, October 30th. UBS Group raised their target price on shares of United Therapeutics from $580.00 to $600.00 and gave the stock a "buy" rating in a research note on Thursday, November 6th. Finally, Weiss Ratings reaffirmed a "buy (b)" rating on shares of United Therapeutics in a report on Monday. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $505.00.
Read Our Latest Research Report on United Therapeutics
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
